Brief: Ryvu Therapeutics Adopts Strategy For 2020-2022

Ryvu Therapeutics SA

16/06/2020 07:14

June 16 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * SAID ON MONDAY MANAGEMENT HAS ADOPTED A NEW STRATEGY FOR
2020-2022
    * PLANS TO COMPLETE PHASE I CLINICAL DEVELOPMENT OF SEL120
IN
ACUTE MYELOID LEUKAEMIA (AML)/MYELODYSPLASTIC SYNDROME (MDS)
    * PLANS TO EXPAND THERAPEUTIC POTENTIAL FOR SEL120 IN SOLID
TUMOURS AND LAUNCH NEW PHASE I STUDY IN SELECTED INDICATIONS IN
PARALLEL TO ONGOING HEMATO-ONCOLOGY STUDIES
    * PLANS TO SUPPORT PHASE II DEVELOPMENT BY MENARINI FOR LEAD
PARTNERED CANDIDATE, SEL24/MEN1703 IN AML
    * PLANS TO COMPLETE PRECLINICAL PROGRAMS FOR A2A/A2B AND
STING
CANDIDATES AND ADVANCE AT LEAST ONE PROGRAM INTO PHASE I OF
CLINICAL TRIALS
    * PLANS TO STRENGTHEN POSITION IN NOVEL TARGET DISCOVERY FOR
SYNTHETIC LETHALITY AND IMMUNE-ONCOLOGY AND IN DEVELOPING NOVEL,
PROPRIETARY DRUG CANDIDATES
    * PLANS TO PARTNER SELECTED EARLY PIPELINE PROGRAMS WITH
BIOTECH
AND PHARMA COMPANIES PROVIDING SYNERGISTIC COMPETENCES AND
RESOURCES, WITH AT LEAST ONE NEW PARTNERING AGREEMENT IN 2020
    * IS TARGETING TO RAISE ABOUT 150 MILLION ZLOTYS FROM SHARE
ISSUE

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nEM1bf55Ma
    
 Further company coverage:  RVU.WA  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10))